Feb. 16: Lube Alert
	A forthcoming research report suggests a number of personal lubricants can damage anal tissue cells and increase HIV replication, potentially heightening the risk of contracting HIV, notably if condoms aren’t used.

	Jan. 31: Fiasco in Florida
	Roughly 6,500 ADAP clients in Florida are about to be cut off from their HIV medications until April. Here's how a group of advocates, a non-profit pharmacy and the pharaceutical industry banded together to prevent a catastrophe.

	Dec. 14: Yolanda Rodriguez-Escobar: Bridging the Gap for Mexican-American Women
	Following years of studying and working—all while raising a family—Yolanda Rodriguez-Escobar recently completed her PhD in social work at the University of Texas at Austin. She is currently a teacher, but previously she founded and held the executive director position at Mujeres Unidas Contra el SIDA in San Antonio. Rodriguez-Escobar tells us the ins and outs of her inspiring work.

	Nov. 23: PrEP Works: The Little Blue Pill That Could
	The results are in—pre-exposure prophylaxis (PrEP) works. The strategy, which involves having people take the daily HIV treatment Truvada to prevent becoming infected with HIV, cut transmission on average by up to 73 percent when taken correctly. While experts are celebrating the news, they are also cautioning that the road from research to rollout of PrEP could be long and complicated.

	Nov. 11: AIDSmeds Video: Quest for a Cure
	On November 3, people living with HIV and their allies gathered in West Hollywood to hear about an exciting new experiment that’s about to get under way. At the meeting, sponsored by the AIDS Policy Project, John Zaia, MD, from the City of Hope in Duarte, California, and Paula Cannon, PhD, from the University of Southern California in Los Angeles, explained the potential behind their new approach to curing AIDS: genetically modifying stem cells taken from people living with both HIV and lymphoma to render their immune systems resistant to HIV.